Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis

作者全名："Zhang, Jindong; Song, Liangdong; Zhu, Huixuan; Liu, Qinyuan; Wang, Delin"

作者地址："[Zhang, Jindong; Song, Liangdong; Zhu, Huixuan; Liu, Qinyuan; Wang, Delin] Chongqing Med Univ, Dept Urol, Affiliated Hosp 1, Chongqing, Peoples R China"

通信作者："Wang, DL (通讯作者)，Chongqing Med Univ, Dept Urol, Affiliated Hosp 1, Chongqing, Peoples R China."

来源：FRONTIERS IN IMMUNOLOGY

ESI学科分类：IMMUNOLOGY

WOS号：WOS:000868199500001

JCR分区：Q1

影响因子：7.3

年份：2022

卷号：13

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：meta-analysis; bladder urothelial carcinoma; programmed cell death ligand-1; prognostic value; radical cystectomy

摘要："BackgroundRadical cystectomy and removal of pelvic lymph nodes (RC-PLND) is a recommended treatment for high-risk non-muscle-invasive and muscle-invasive non-metastatic bladder cancer (BC). However, 50% of patients relapse after RC-PLND. This study aimed to evaluate the effect of programmed cell death ligand-1 (PD-L1) on the prognosis of bladder urothelial carcinoma (BUC) after RC-PLND. MethodsWe present this meta-analysis according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Guidelines. The main outcomes were overall survival (OS), recurrence-free survival (RFS), and cancer-specific survival (CSS) of 3 and 5 years after RC-PLND. ResultsOverall, 11 studies and 1393 BUC cases were included in our meta-analysis. In tumor cells (TCs), the PD-L1 negative group had statistically significant advantage in 5-year OS (risk ratio [RR]: 0.85, 95% confidence interval [CI]: 0.74-0.97, P = 0.02), RFS (RR: 0.76, 95% CI: 0.58-0.99, P = 0.04), and CSS (RR: 0.73, 95% CI: 0.58-0.92, P = 0.009) compared with the PD-L1 positive group. But, no statistically significant difference in 5-year OS and RFS was observed between the PD-L1 negative and positive groups in tumor-infiltrating immune cells. ConclusionsOur study found that patients with BUC who tested positive for PD-L1 in TCs had a poor prognosis after RC-PLND. PD-1 or PD-L1 inhibitors could be used as a adjuvant medication for patients with BUC after RC-PLND who exhibit PD-L1 overexpression in TCs. Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022301424."

基金机构：Natural Science Foundation of Chongqing; Chongqing Science and Technology Commission and Technology Commission; [cstc2019jcyj-msxmX0732]; [cstc2017shms-zdyf0319]

基金资助正文："Funding This work was supported by grants from the Natural Science Foundation of Chongqing (cstc2019jcyj-msxmX0732), and Chongqing Science and Technology Commission and Technology Commission (cstc2017shms-zdyf0319)."